Does ALZN pay a dividend and is it safe?

Alzamend Neuro Inc. (ALZN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ALZN / dividends

ACXP (33) BGMS (38) SKYE (34) APRE (40) ⌘ Pro Terminal →

Alzamend Neuro Inc. (ALZN) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.25 +3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.26

Alzamend Neuro Inc. (ALZN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $5.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALZN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.25 (+3.31% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALZN ranks #656 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALZN compare to ACXP and BGMS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and BGMS (Bio Green Med Solution Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALZN?

▼

Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $24.5M in revenue (+95.0% YoY), -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.26 (+0.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALZN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY ALZN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.35-3.7% Next Q

Q2 (-2Q)

Grade E$1.30-13.1% Next Q

Q3 (-1Q)

Grade E$1.13+10.6% Next Q

Current

Grade E$1.25-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALZN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALZN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.52) and Max Pain ($1.31) forces dealer call-delta covering toward $2.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALZN Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALZN)

✓Walkthrough of ALZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.61%📐 HORIZONTAL RANGE

2026-11-03O $1.22H $1.25L $1.21C $1.25VOL 25.0K

RES: $2.18SUP: $1.05SMA50: $1.52SMA200: $1.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALZN Butterfly Map → + Track ALZN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALZN)

Health Care Rank #656 of 1016 ⚔️ ACXP vs ALZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALZN vs. ACXP, BGMS, SKYE, APRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alzamend Neuro Inc. (ALZN) ranks #656 by composite RQD confidence (34/100, grade E) and #928 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, ALZN leads on earnings valuation at N/A trailing P/E, while ALZN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ALZN at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALZN ACTIVE Alzamend Neuro Inc.	E	34/100	—	—	-35.0%	+3.31%	$5.8M	Benchmark Subject
ACXP Acurx Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	+2.89%	$5.8M	/acxp-vs-alzn →
BGMS Bio Green Med Solution Inc.	D-	38/100	—	—	-35.0%	0.00%	$6.0M	/bgms-vs-alzn →
SKYE Skye Bioscience Inc.	E	34/100	—	—	-35.0%	+3.13%	$5.7M	/skye-vs-alzn →
APRE Aprea Therapeutics Inc.	D-	40/100	—	—	-35.0%	+1.32%	$6.1M	/apre-vs-alzn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001677077

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported GAAP revenue of $24.5M (+95.0% vs. FY2024 revenue of $12.6M , and -11.8% cumulative change since FY2023) , GAAP net income of -$8.8M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-22.8% YoY). On the balance sheet, ALZN closed FY2025 with $4.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$24.5M	-$8.8M	-$8.1M	-$8.1M	$4.0M	—
FY2024 (FY)	2025-04-30	$12.6M	-$4.5M	-$6.6M	-$6.6M	$4.2M	—
FY2023 (FY)	2024-04-30	$27.8M	-$9.9M	-$8.3M	-$8.3M	—	—

3. ALZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALZN compare to ACXP and BGMS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALZN?

Where is ALZN trading relative to its 50-day, 200-day, and 52-week technical levels?

ALZN last traded at $1.25 (+3.31% on volume of 37,066 shares), positioning the stock -17.76% below its 50-day simple moving average ($1.52) and -14.38% below its 200-day simple moving average ($1.46). Across its 52-week range of $0.84 to $2.61, ALZN sits at the 23.2% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

Direct Sub-Reports: ALZN RQD Cockpit ALZN 12M Forecast ALZN Earnings & Move ALZN Dividends & DRIP ALZN Insiders & 13F ALZN Whale Options ALZN Profit Sankey ALZN News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALZN — Alzamend Neuro Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:55Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ALZN scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 8 / 20 (ROIC -35%; FCF yield 0%). Negative return on invested capital and zero free-cash-flow yield indicate the business is consuming capital rather than generating it.
Whale / 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the weakest pillar, suggesting little supportive institutional demand in the source data.
Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider and congressional signals are weak.
Macro Regime Fit: 9 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the broader market, with no defensive cushion indicated.
Forensic Balance Sheet: 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The Piotroski F-Score of 1 out of 9 is a notably weak reading on financial health.

For a prospective investor, the rating implies that upside depends on a turnaround in cash generation that the reported financials do not yet show, while the balance sheet and flow pillars offer limited support.9M against reported net losses of -$8.8M in FY 2025 frames the risk profile. This is an analytical summary, not personalized financial advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alzamend Neuro Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $0.0B. Products, customers, and revenue model are — Reported revenue is — across the periods provided.

The company reported no revenue and operating losses in each period shown, with gross, operating, and net margins all at 0% in the market data. ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1 out of 9, with Debt/Equity at 0.5. Cash declined from $3.4M to $2.7M between FY 2024 and FY 2025 while free cash flow remained negative.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $0.84 – $2.61 52-week range.
🐻 Primary Bear Case: Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sheet. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the Beta of 1.0 are — Investors should watch for disclosures on suppliers, partners, and clinical or licensing dependencies, none of which appear in the source data.

Key Question #1: What are the company's products, clinical programs, or licensing arrangements, and what revenue, if any, is expected?
Key Question #2: What is the cash runway given $2.7M of cash against FY 2025 free cash flow of -$8.1M?
Key Question #3: What is the debt position, since reported debt is N/A while Debt/Equity is 0.5?

ALZN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alzamend Neuro Inc. (ALZN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALZN Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 20h ago

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 23h ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

What Makes Allegion (ALLE) a New Buy Stock

Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Alzamend Neuro (ALZN) Rises 4.26% to $1.34 as Shares Press Toward Range Resistance - Sector ETF Flow

https://www.dars.gov.et/ report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

ZenaTech, Inc. (ZENA) Upgraded to Buy: What Does It Mean for the Stock?

Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Alpine Income (PINE) Upgraded to Strong Buy: Here's What You Should Know

Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALZN Bull vs. Bear Conversation Board — What's Your Call at $1.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALZN 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.56 (+28.9%)

📌 Pinned Debate

A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum.

The street is overcomplicating Alzamend Neuro Inc. (ALZN). A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.31.

VolSurface_Trader 🐂 BULL

Both sides have a point here — ALZN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.99 (-18.2%)

Spot @ $1.21

Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sh

Sitting on the sidelines or leaning short ALZN above $1.21. Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sheet.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.61.